Evidence map›Paper›PMID 24960127›Full record

ArticlePloS one2014

tLivin displays flexibility by promoting alternative cell death mechanisms.

Tamar Shiloach, Christian Berens, Christina Danke, Ortal Waiskopf, Riki Perlman, Dina Ben-Yehuda

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Tamar ShiloachDivision of Hematology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
Christian BerensDepartment of Biology/Microbiology, Friedrich-Alexander-Universitaet Erlangen-Nuernberg, Erlangen, Germany.
Christina DankeDepartment of Biology/Microbiology, Friedrich-Alexander-Universitaet Erlangen-Nuernberg, Erlangen, Germany.
Ortal WaiskopfDivision of Hematology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
Riki PerlmanDivision of Hematology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
Dina Ben-YehudaDivision of Hematology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
Hadassah Medical Center · ILFriedrich-Alexander-Universität Erlangen-Nürnberg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Livin is a member of the Inhibitor of Apoptosis (IAP) protein family that inhibits apoptosis triggered by a variety of stimuli. We previously demonstrated that while Livin inhibits caspase activity, caspases can cleave Livin to produce a truncated protein, tLivin and that this newly formed tLivin paradoxically induces cell death. However to date, the mechanism of tLivin-induced cell death is not fully understood. In this study, we set out to characterize the form of cell death mediated by tLivin. Here we demonstrate that, unlike most death-promoting proteins, tLivin is a flexible inducer of cell death capable of promoting necrosis or apoptosis in different cell lines. The unusual flexibility of tLivin is displayed by its ability to activate an alternative form of cell death when apoptosis is inhibited. Thus, tLivin can promote more than one form of cell death in the same cell type. Interestingly, in cells where tLivin induces necrosis, deletion of the caspase binding BIR domain results in tLivin-induced apoptosis, suggesting the BIR domain can potentially hamper the ability of tLivin to induce apoptosis. We further elucidate that tLivin activates the JNK pathway and both tLivin-induced apoptosis and necrosis are partially mediated by JNK activity. Acquired resistance to apoptosis, common in many tumors, impinges on the efficiency of conventional anti-cancer agents that function primarily by inducing apoptosis. The ability of tLivin to induce death of apoptosis-compromised cells makes it an attractive candidate for targeted cancer therapy.

Indexed as

Adaptor Proteins, Signal TransducingApoptosisCaspasesCell DeathCell LineHumansInhibitor of Apoptosis ProteinsMAP Kinase Signaling SystemNecrosisNeoplasm ProteinsProtein Structure, TertiaryAdaptor Proteins, Signal TransducingBIRC7 protein, humanCaspasesInhibitor of Apoptosis ProteinsNeoplasm Proteins

Identifiers

PMID24960127
PMCPMC4069184
OpenAlexW2063275170

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.